Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody

Sci Transl Med. 2017 Apr 5;9(384):eaai8711. doi: 10.1126/scitranslmed.aai8711.


As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Cross Protection
  • Filoviridae / physiology*
  • Filoviridae Infections / drug therapy*
  • Filoviridae Infections / virology
  • Guinea Pigs
  • Humans
  • Macaca fascicularis
  • Macaca mulatta
  • Marburg Virus Disease / drug therapy*
  • Marburg Virus Disease / virology
  • Marburgvirus / physiology*
  • Pilot Projects


  • Antibodies, Monoclonal